{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:18:06Z","timestamp":1777645086029,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.neuint.2012.08.005","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T14:46:13Z","timestamp":1345560373000},"page":"1133-1143","source":"Crossref","is-referenced-by-count":9,"title":["Structural insight into receptor-selectivity for lurasidone"],"prefix":"10.1016","volume":"61","author":[{"given":"Osamu","family":"Ichikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nakahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Horisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2012.08.005_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000418010","article-title":"Positive and negative symptoms: historical and conceptual aspects","volume":"24","author":"Andreasen","year":"1990","journal-title":"Mod. Probl. Pharmacopsychiatry"},{"key":"10.1016\/j.neuint.2012.08.005_b0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"Integrated methods for the construction of three-dimensional models and computational probing of structure\u2013function relations in G protein-coupled receptors","volume":"25","author":"Ballesteros","year":"1995","journal-title":"Methods Neurosci."},{"key":"10.1016\/j.neuint.2012.08.005_b0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuint.2009.05.004","article-title":"Molecular modelling of subtypes (\u03b12A, \u03b12B and \u03b12C) of \u03b12-adrenoceptors: a comparative study","volume":"55","author":"Balogh","year":"2009","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2012.08.005_b0020","first-page":"216","article-title":"The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site","volume":"49","author":"Befort","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuint.2012.08.005_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcc.540040211","article-title":"CHARMM: a program for macromolecular energy, minimization, and dynamics calculations","volume":"4","author":"Brooks","year":"1983","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuint.2012.08.005_b0035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1126\/science.1197410","article-title":"Structure of the human dopamine D3 receptor in complex with a D2\/D3 selective antagonist","volume":"330","author":"Chien","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuint.2012.08.005_b0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0269881105058378","article-title":"Weight change with atypical antipsychotics in the treatment of schizophrenia","volume":"19","author":"Haddad","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuint.2012.08.005_b0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10753","article-title":"Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist","volume":"482","author":"Haga","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2012.08.005_b0050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","article-title":"Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone","volume":"127","author":"Harvey","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuint.2012.08.005_b0055","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/S0006-3495(03)74712-2","article-title":"An implicit membrane generalized born theory for the study of structure, stability, and interactions of membrane proteins","volume":"85","author":"Im","year":"2003","journal-title":"Biophys. J."},{"key":"10.1016\/j.neuint.2012.08.005_b0060","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/jcc.10321","article-title":"Generalized born model with a simple smoothing function","volume":"24","author":"Im","year":"2003","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuint.2012.08.005_b0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuint.2012.08.005_b0070","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1248\/cpb.43.2139","article-title":"Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis-cyclohexanedicarboximide (SM-9018) and related compounds","volume":"43","author":"Ishizumi","year":"1995","journal-title":"Chem. Pharm. Bull (Tokyo)"},{"key":"10.1016\/j.neuint.2012.08.005_b0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature10867","article-title":"Structure and dynamics of the M3 muscarinic acetylcholine receptor","volume":"482","author":"Kruse","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2012.08.005_b0080","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.str.2011.05.012","article-title":"Participants, 2011. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment","volume":"19","author":"Kufareva","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.neuint.2012.08.005_b0085","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Cryst."},{"key":"10.1016\/j.neuint.2012.08.005_b0090","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1017\/S0033291709005455","article-title":"Second-generation antipsychotics for schizophrenia: can we resolve the conflict?","volume":"39","author":"Leucht","year":"2009","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuint.2012.08.005_b0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/bioinformatics\/btk023","article-title":"OPM: orientations of proteins in membranes database","volume":"22","author":"Lomize","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neuint.2012.08.005_b0100","unstructured":"Mackerell, A.D., Jr., Brooks, B.R., Brooks, C.L., 3rd, Nilsson, L., Roux, B., Won, Y., Karplus, M., 1998. CHARMM: The Energy Function and Its Parameterization with an Overview of the Program, in: Schleyer, P.v.R., Allinger, N.L., Clark, T., Gasteiger, J., Kollman, P.A., Schaefer, H.F., 3rd, Schreiner, P.R. (Eds.), The Encyclopedia of Computational Chemistry. vol. 1, John Wiley & Sons, Chichester, pp. 271 -277."},{"key":"10.1016\/j.neuint.2012.08.005_b0105","unstructured":"Maruyama, M., 2011. A cycloalkane derivative. WO\/2011\/002103."},{"key":"10.1016\/j.neuint.2012.08.005_b0110","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1021\/ci900444q","article-title":"Homology modeling and docking evaluation of aminergic G protein-coupled receptors","volume":"50","author":"McRobb","year":"2010","journal-title":"J. Chem. Info. Model."},{"key":"10.1016\/j.neuint.2012.08.005_b0115","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0006-3223(99)00255-3","article-title":"Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions","volume":"46","author":"Meltzer","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2012.08.005_b0120","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuint.2012.08.005_b0125","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2012.08.005_b0130","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuint.2012.08.005_b0135","first-page":"21","article-title":"Discovery of antipsychotic lurasidone","volume":"20","author":"Nagata","year":"2010","journal-title":"Med. Chem. News"},{"key":"10.1016\/j.neuint.2012.08.005_b0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuint.2012.08.005_b0145","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1357-4310(95)91170-7","article-title":"Comparative protein modeling by satisfaction of spatial restraints","volume":"1","author":"Sali","year":"1995","journal-title":"Mol. Med. Today"},{"key":"10.1016\/j.neuint.2012.08.005_b0150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/prot.340230306","article-title":"Evaluation of comparative protein modeling by MODELLER","volume":"23","author":"Sali","year":"1995","journal-title":"Proteins"},{"key":"10.1016\/j.neuint.2012.08.005_b0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/TCRM.S12701","article-title":"Clinical potential of lurasidone in the management of schizophrenia","volume":"7","author":"Samalin","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.neuint.2012.08.005_b0160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2012.08.005_b0165","doi-asserted-by":"crossref","first-page":"40989","DOI":"10.1074\/jbc.M206801200","article-title":"Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch","volume":"277","author":"Shi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuint.2012.08.005_b0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature10236","article-title":"Structure of the human histamine H1 receptor complex with doxepin","volume":"475","author":"Shimamura","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2012.08.005_b0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1093-3263(02)00164-X","article-title":"LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites","volume":"21","author":"Venkatachalam","year":"2003","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.neuint.2012.08.005_b0180","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neuint.2009.06.006","article-title":"Molecular docking study of A3 adenosine receptor antagonists and pharmacophore-based drug design","volume":"55","author":"Wei","year":"2009","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2012.08.005_b0185","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jcc.10306","article-title":"Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm","volume":"24","author":"Wu","year":"2003","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuint.2012.08.005_b0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/DDDT.S11180","article-title":"Update on the development of lurasidone as a treatment for patients with acute schizophrenia","volume":"6","author":"Yasui-Furukori","year":"2012","journal-title":"Drug Des. Dev. Ther."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018612002562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018612002562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T09:55:40Z","timestamp":1542794140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018612002562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0197018612002562"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2012.08.005","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}